Incannex Wins R&D Award for Oral Obstructive Sleep Apnea Therapy

Reuters01-15

Incannex Wins R&D Award for Oral Obstructive Sleep Apnea Therapy

Incannex Healthcare Inc. has been recognized with the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination therapy aimed at treating obstructive sleep apnea (OSA). The award highlights Incannex’s research-driven approach and the significance of developing innovative, evidence-based alternatives to device-based OSA therapies. The company’s IHL-42X program is advancing into late-stage development, with a focus on addressing unmet medical needs for patients struggling with current treatment options. The recognition reflects the industry-wide relevance of Incannex’s ongoing research in respiratory medicine. The announcement pertains to the award and does not specify the presentation of detailed scientific research results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-004488), on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603607833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603607833","market":"fut","top_or_hot":-1,"title":"Incannex Wins R&D Award for Oral Obstructive Sleep Apnea Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex Wins R&amp;D Award for Oral Obstructive Sleep Apnea Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. has been recognized with the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination therapy aimed at treating obstructive sleep apnea (OSA). The award highlights Incannex’s research-driven approach and the significance of developing innovative, evidence-based alternatives to device-based OSA therapies. The company’s IHL-42X program is advancing into late-stage development, with a focus on addressing unmet medical needs for patients struggling with current treatment options. The recognition reflects the industry-wide relevance of Incannex’s ongoing research in respiratory medicine. The announcement pertains to the award and does not specify the presentation of detailed scientific research results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-004488), on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex Wins R&D Award for Oral Obstructive Sleep Apnea Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex Wins R&D Award for Oral Obstructive Sleep Apnea Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex Wins R&amp;D Award for Oral Obstructive Sleep Apnea Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. has been recognized with the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination therapy aimed at treating obstructive sleep apnea (OSA). The award highlights Incannex’s research-driven approach and the significance of developing innovative, evidence-based alternatives to device-based OSA therapies. The company’s IHL-42X program is advancing into late-stage development, with a focus on addressing unmet medical needs for patients struggling with current treatment options. The recognition reflects the industry-wide relevance of Incannex’s ongoing research in respiratory medicine. The announcement pertains to the award and does not specify the presentation of detailed scientific research results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-004488), on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IXHL","symbol_name":"INCANNEX HEALTHCARE LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL6x7Yld:1","article_id":"2603607833","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603607833","pubTimestamp":1768480285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incannex Healthcare Inc. has been recognized with the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination therapy aimed at treating obstructive sleep apnea . The award highlights Incannex’s research-driven approach and the significance of developing innovative, evidence-based alternatives to device-based OSA therapies. The company’s IHL-42X program is advancing into late-stage development, with a focus on addressing unmet medical needs for patients struggling with current treatment options. The recognition reflects the industry-wide relevance of Incannex’s ongoing research in respiratory medicine. The announcement pertains to the award and does not specify the presentation of detailed scientific research results.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"translate_title":"Incannex获得口腔阻塞性睡眠呼吸暂停治疗研发奖","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Incannex Wins R&D Award for Oral Obstructive Sleep Apnea Therapy\n    \n\nIncannex Healthcare Inc. has been recognized with the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination therapy aimed at treating obstructive sleep apnea (OSA). The award highlights Incannex’s research-driven approach and the significance of developing innovative, evidence-based alternatives to device-based OSA therapies. The company’s IHL-42X program is advancing into late-stage development, with a focus on addressing unmet medical needs for patients struggling with current treatment options. The recognition reflects the industry-wide relevance of Incannex’s ongoing research in respiratory medicine. The announcement pertains to the award and does not specify the presentation of detailed scientific research results.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-004488), on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603607833","isCrawlerRequest":true}